BioWorld

Jan. 8, 2004

PTC To Fund Drug Development Through $35M Financing Round

PTC Therapeutics Inc. raised $35 million to support its initial clinical drug development activities and other product research. (BioWorld Today) Read More

Elan's Former Neurex Product, Prialt, Hits Phase III Endpoint

New Drug Efalizumab OK'd By FDA But Not As Definitive Cure; Psoriasis Still Plagues Legions

Thios Adds To Pipeline Through TS1 Licensing Deal With Wyeth

Forbes Medi-Tech Private Placement Raises $10.75M

Other News To Note

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...